Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin (NASDAQ: AMRN) reported new post hoc data from the REDUCE-IT placebo arm at the 2026 European Atherosclerosis Society Congress. In 3,485 statin-treated patients with elevated triglycerides followed for 4.9 years, risk-weighted apoB (RW-apoB) averaged about 30% higher than measured apoB and more effectively identified residual cardiovascular risk than LDL-C, non-HDL-C, or apoB.
Applying ESC intervention thresholds, RW-apoB classified more patients as high risk, suggesting potential value for improved risk stratification in routine care.
Amarin (NASDAQ: AMRN) reported Q1 2026 results: Total net revenue $45.1M (up 7% vs Q1 2025), product revenue $43.3M, licensing & royalties $1.8M (up 84%), and cash of $307.8M as of March 31, 2026. Operating expenses fell 31% to $29.1M; operating loss narrowed to $(11.3)M and net loss improved to $(10.5)M.
The company generated positive cash flow for a second consecutive quarter, reiterated expectation for full-year 2026 positive cash flow, and cited international partnership-driven European growth and updated clinical guidelines supporting icosapent ethyl.
Amarin (NASDAQ: AMRN) will report first quarter 2026 financial results and host a conference call on Wednesday, April 29, 2026.
The company will release results in pre-market hours and hold a live call at 8:00 a.m. ET, with telephone dial-in, webcast access on the Investor Relations website, and a replay available online until 10/29/26.
Amarin (NASDAQ: AMRN) highlighted ACC Scientific Sessions 2026 findings stressing that elevated triglycerides drive residual cardiovascular risk despite LDL-C control and that icosapent ethyl (IPE) can reduce events when added to statins.
Amarin-supported REDUCE-IT post hoc analysis found significant CV event reduction in extreme and very high-risk patients; plaque-imaging studies EVAPORATE and CHERRY showed favorable coronary plaque effects with EPA.
Amarin (NASDAQ: AMRN) welcomed the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline update endorsing a broader approach to residual cardiovascular risk and recognizing icosapent ethyl (IPE) as an evidence-based adjunct for statin-treated patients with elevated triglycerides. The guideline highlights IPE's role in reducing ASCVD events beyond LDL-C lowering.
Amarin (NASDAQ: AMRN) announced additional REDUCE-IT subgroup analyses and mechanistic EPA data will be presented at the American College of Cardiology Annual Scientific Session & Expo, March 28-30, 2026 in New Orleans.
Highlighted presentations include a REDUCE-IT secondary analysis on patients at extreme cardiovascular risk (oral, March 29, 12:30pm CST) and an EPA inhibition of Lp(a) oxidation poster (March 28, 11:00am CST).
Amarin (NASDAQ: AMRN) highlighted a post hoc REDUCE-IT analysis published March 2026 in the European Journal of Preventive Cardiology showing icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost to hospitalization and death among 8,179 statin-treated participants followed for a median of five years.
The paper underscores patient-centered benefits of IPE (VASCEPA/VAZKEPA) and notes prior REDUCE-IT results influenced guideline inclusion.
Amarin (NASDAQ: AMRN) reported Q4 and full‑year 2025 results showing operational improvements and a tighter cost base. Total net revenue was $49.2M in Q4 (down 21% YoY); operating loss narrowed to $6.3M; cash and investments were $302.6M with no debt.
The company realized $31M of targeted $70M cost savings and recorded $36.2M of restructuring charges in 2025, with remaining charges expected in early 2026. The company finalized a long‑term European license and supply agreement for VAZKEPA and retained U.S. VASCEPA market leadership.
Amarin (NASDAQ: AMRN) used American Heart Month (Feb 23, 2026) to urge urgent action on underutilized, guideline‑supported cardiovascular therapies.
The company highlighted that 48.9% of U.S. adults live with CVD and cited evidence that cumulative CV event incidence can reach ~40% over 10 years, calling to “Review, Reassess, Refocus” care to close treatment gaps.
Amarin (NASDAQ: AMRN) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A pre-market press release will be issued, followed by a conference call with senior management at 8:00 a.m. ET.
Investors can join via telephone (US: 888-506-0062; international: 973-528-0011, access code 675507) or via webcast on the company Investor Relations website. A replay will be available online and by phone through August 25, 2026.